Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Stopped out of IRSN at .18.
TLR, AMEX/Gold getting a boost. $1.05
Gold at HOD, $1,236...
Betting on IRSN at .20.
Stop at mid 18s.
IRSN just surged to .21. hmmm
VGZ at HOD /$1.93.
I was looking as IRSN too, possible RS to become Nas compliant?
Watching. Good volume.
In VGZ 1.87ish.
Gold at 1234.
Wow Intel buys Mcafee, pushing it up $17.
Considering VGZ and BSDM myself, so far.
Nevermind on BSDM, news of dilution this am.
YW, great volume too for easy exits. How did that one get by you?
I remember buying GSS for about 80 cents, look at it now.
Thought I made a killing selling for 90. lol
That pales in comparison to my Pilgrims Pride folly though.
PEIX, Ill look for a dip then for a 2nd entry.
RAS hod 1.61.
Sold PEIX at .745 from .645. +.10
Not sure where its going, but I got mine.
No looking back.
Too many times my greed turned to losses.
Good luck to anyone still in.
That would be awesome. In avg .645.
Stop set at .70.
PEIX, .77 HOD-handled that profit taking well. Excellent volume.
PEIX made 1.43 net. I doubled my position at .66, nearly all in.
PEIX pushing .73 on earnings!
VGZ is looking real good lately.
OSTE buyout up 63%.
Exited RAS at 1.59, +.03.
PEIX up 23%, in at .63.
Xoma gapping up a penny.
PTN news gap.AMEX .22
PTN gapping on news:
Palatin Technologies, Inc. Announces Positive Safety Results in Subcutaneous Bremelanotide Trial in Men
0 minutes ago - Pr Newswire
Related Companies
Symbol Last %Chg
PTN 0.205 0.00%
As of 3:59 PM ET 8/16/10
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without sustained clinically significant blood pressure effects and support the continued development of bremelanotide.
As part of the analysis of the effects of bremelanotide on blood pressure, the Company engaged an independent panel of cardiovascular experts to evaluate both study results and an integrated cardiovascular safety analysis conducted on data from completed bremelanotide studies. Based on recommendations from the outside panel and its own internal review, Palatin intends to engage the Food and Drug Administration (FDA) in discussions regarding clinical trial designs to further study bremelanotide for the treatment of sexual dysfunction.
Palatin expects to meet with the FDA in the fourth quarter of calendar year 2010 to discuss initiation of a Phase 2 study of subcutaneously administered bremelanotide, as a monotherapy and as a combination therapy with a PDE-5 inhibitor such as sildenafil (Viagra(R)), for men with ED who are not responsive or inadequately responsive to PDE-5 inhibitor therapies alone.
The objective of the placebo-controlled, randomized, double-blind, cross over safety study was evaluation of blood pressure effects of subcutaneous bremelanotide in healthy male volunteers between 45 and 65 years old. The study also evaluated dose-to-dose consistency of plasma exposure of bremelanotide. A total of 49 subjects were dosed in the safety study; nineteen of the subjects were enrolled in a sub-study and completed a graded exercise treadmill test as a surrogate for the cardiovascular effects of sexual activity.
"The commercial opportunity of bremelanotide for sexual dysfunction is significant. About 35% of patients with ED do not respond to approved oral therapies, and with limited treatment options these patients are ideal candidates for subcutaneous bremelanotide," stated Carl Spana, Ph.D., President and CEO of Palatin. "Plus, we have an additional opportunity with female sexual dysfunction (FSD), which also represents a large market opportunity with no FDA approved drugs."
About Erectile Dysfunction (ED)
Erectile dysfunction is the consistent inability to attain and maintain an erection sufficient for sexual intercourse. Up to 35% of men are non-responsive to standard therapies with phosphodiesterase-5 inhibitors such as sildenafil (Viagra(R)), vardenafil (Levitra(R)) and tadalafil (Cialis(R)). The current worldwide market for ED drugs is over $4.0 billion. There are limited therapeutic options for ED patients non-responsive to phosphodiesterase-5 inhibitor therapy, including alprostadil for direct penis injection or urethral suppositories, surgical penile implants and various devices.
About Female Sexual Dysfunction (FSD)
FSD includes four disorders, hypoactive sexual desire disorder, female sexual arousal disorder, sexual pain disorder and orgasmic disorder. To establish a diagnosis of FSD, these syndromes must be associated with personal distress, as determined by the affected woman. A February 10, 1999 study published in the Journal of the American Medical Association, titled, "Sexual Dysfunction in the United States: Prevalence and Predictors," states that approximately 43% of women suffer from some form of FSD. There are no drugs in the United States approved for FSD indications.
About Bremelanotide
Bremelanotide, a synthetic peptide developed and solely owned by Palatin Technologies, is believed to act through activation of melanocortin receptors in the central nervous system. Nasal formulations of bremelanotide have been extensively studied, including Phase 2B studies for erectile dysfunction in both non-diabetic and diabetic patients and Phase 2A studies for female sexual dysfunction in both pre- and post-menopausal women. Increases in blood pressure observed in some patients receiving nasally administered bremelanotide, coupled with significant variation in plasma levels, lead to discontinuation of nasally administered bremelanotide as a first-line therapy for sexual dysfunction. Palatin is developing subcutaneous bremelanotide as a therapeutic for treatment of men with erectile dysfunction who are non-responsive to standard therapies with phosphodiesterase-5 inhibitors such as sildenafil and for treatment of women with female sexual dysfunction.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonists with a focus on melanocortin and natriuretic peptide receptor systems. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at www.palatin.com.
Forward-looking Statements
Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc. such as statements about bremelanotide clinical trial results, potential actions by regulatory agencies including the U.S. Food and Drug Administration (FDA), proposed indications for bremelanotide, timing, duration, cost and results of proposed clinical trials with bremelanotide, regulatory plans with bremelanotide, and market potential for bremelanotide, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.
SOURCE Palatin Technologies, Inc.
RAS, all in @ 1.56.
Stop loss at high 1.40s tomorrow.
Hoping for 1.70-1.90 in the next day or 2...
last post today, thanks for the chart when you get to it Sean.
Here they are:
VGZ 1.6601 +0.19 +12.93 945,260 1.66 1.68
ANV 20.33 +0.84 +4.31 365,515 20.32 20.33
CXZ 0.135 +0.005 +3.85 83,651 0.134 0.135
GBG 1.92 +0.07 +3.78 1,756,614 1.91 1.92
EXK 3.38 +0.12 +3.68 180,003 3.37 3.38
IAG 18.27 +0.60 +3.40 1,678,663 18.26 18.27
CDE 15.01 +0.47 +3.23 760,370 15.01 15.02
SLW 20.52 +0.64 +3.22 2,513,209 20.51 20.52
HL 4.945 +0.105 +2.17 1,982,837 4.94 4.95
NGD 5.68 +0.12 +2.16 954,441 5.68 5.69
NG 6.71 +0.14 +2.13 763,180 6.71 6.72
GSS 4.48 +0.08 +1.82 998,336 4.47 4.48
MNEAF 0.82 +0.01 +1.23 93,545 0.80 0.819
NXG 2.92 +0.03 +1.04 388,020 2.92 2.93
TGB 4.25 +0.04 +0.95 1,053,547 4.25 4.26
TC 8.96 +0.08 +0.90 630,855 8.96 8.97
EGI 2.2398 +0.011 +0.48 35,516 2.23 2.25
AGT 0.00 0.00 0.00 0 0.00 0.00
RBY 3.97 -0.05 -1.24 300,336 3.97 3.98
MMG 0.72 -0.05 -6.49 31,251 0.7105 0.7199
Gold Volume leaders:
SLW 20.52 +0.64 +3.22 2,522,944 20.52 20.53
HL 4.95 +0.11 +2.27 1,983,137 4.94 4.95
GBG 1.9193 +0.069 +3.75 1,761,614 1.91 1.92
IAG 18.26 +0.59 +3.34 1,681,363 18.26 18.27
TGB 4.258 +0.048 +1.14 1,058,316 4.25 4.26
GSS 4.49 +0.09 +2.05 1,027,684 4.48 4.49
NGD 5.68 +0.12 +2.16 956,445 5.68 5.69
VGZ 1.6601 +0.19 +12.93 946,560 1.66 1.67
Top Gold Producers:
AU 43.93 +1.02 +2.38 892,850 43.94 43.95
NEM 57.72 +1.00 +1.76 1,802,306 57.71 57.72
GFI 14.20 +0.24 +1.72 1,786,605 14.19 14.20
ABX 43.62 +0.70 +1.63 3,455,421 43.62 43.63
KGC 15.2034 +0.043 +0.29 3,182,746 15.20 15.21
HMY 10.79 -0.10 -0.92 1,696,250 10.78 10.79
FYI Here are my oil and gas watchlist:
FPP 3.59 +0.16 +4.66 9,960 3.60 3.63
EXXI 16.85 +0.60 +3.69 334,725 16.84 16.86
END 1.16 +0.03 +2.65 57,866 1.15 1.16
XTEX 12.44 +0.20 +1.63 191,420 12.43 12.45
ERHE 0.375 +0.005 +1.35 33,700 0.375 0.38
CHK 20.9121 +0.132 +0.64 5,719,907 20.91 20.92
IVAN 1.58 +0.01 +0.64 380,815 1.58 1.59
BCON 0.321 +0.002 +0.63 500,053 0.321 0.3211
DNE 0.14 0.00 0.00 0 0.00 0.22
CMZ 0.647 0.00 0.00 0 0.55 0.80
TIV 0.774 -0.001 -0.13 11,560 0.7738 0.78
APL 16.75 -0.15 -0.89 438,112 16.74 16.75
GMET 1.00 -0.01 -0.99 16,666 1.00 1.01
CPE 5.11 -0.09 -1.73 168,190 5.10 5.11
UNG 7.0901 -0.20 -2.74 10,913,284 7.09 7.10
RTK 0.91 -0.028 -3.01 509,415 0.905 0.91
EEE 0.1545 -0.006 -3.44 2,121,005 0.1546 0.1575
QTWW 0.5035 -0.023 -4.28 151,799 0.5038 0.5079
DEJ 0.3514 -0.024 -6.29 184,701 0.3507 0.357
CFW 0.80 -0.08 -9.09 313,351 0.795 0.80
Uranium:
URRE 0.5513 +0.051 +10.26 245,668 0.5513 0.559
DNN 1.42 +0.07 +5.19 186,737 1.42 1.43
CXZ 0.135 +0.005 +3.85 83,651 0.134 0.135
UEC 2.50 +0.07 +2.88 205,776 2.49 2.50
URZ 1.21 +0.01 +0.83 46,647 1.20 1.21
URST 0.35 0.00 0.00 0 0.35 0.37
URHN 0.0032 0.00 -3.03 212,929 0.0031 0.0033
Double Digit Divy list (probably outdated)
NRF 3.5895 +0.15 +4.35 398,294 3.58 3.59
TICC 9.22 +0.31 +3.48 191,629 9.21 9.22
PEI 11.36 +0.13 +1.16 437,714 11.33 11.35
MPW 9.54 +0.08 +0.85 252,888 9.54 9.55
GMR 5.13 +0.04 +0.79 574,488 5.12 5.13
WIN 11.37 +0.04 +0.35 2,457,379 11.37 11.38
FTR 7.6015 +0.002 +0.02 5,227,591 7.60 7.61
HRP 0.00 0.00 0.00 0 0.00 0.00
KCAP 5.02 0.00 0.00 31,911 5.00 5.03
PDLI 5.15 -0.03 -0.58 5,535,381 5.15 5.16
PVX 6.32 -0.04 -0.63 766,790 6.31 6.32
MMG and RBY are the only red gold stocks on my watch list of 21 stocks.
VGZ leads the pack.
Coin, decent 2-3 cent bounce from .43 alert.
COCO, up .41 from my $5 buy this am, I got stopped out at 4.94. :(
Hey, it was a good idea! hahah
Had a target of 5.50, looks like it might get there.
Whats driving the volume on Heli I wonder.(otc)
COIN drop, possible bounce from .43.(In at .43)
Stop at .40.
Looking not too good at this point.
EMKR added to my watchlist. GL!
COC0 bouncing w/o my hand in their pocket, $5.35.
LMAO! hahahah
Stopped out of COCO at 4.94.
win some lose some.
Good call on ALY.
Risking a $5 COCO scalp on big drop.
Blood/street/fear.
Hoping for 50 cents.
Set stop loss at 4.94.
Trying some Dell at 11.82.Out @ $12.
Dell buys PAR, up from $9 to 18 buyout price.
considering buying some Dell at 12.
Good luck, I agree more news and it will bust 3 again easily.
I may hop in on Monday.